| 11.62 0.02 (0.17%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.22 | 1-year : | 16.61 |
| Resists | First : | 12.18 | Second : | 14.22 |
| Pivot price | 9.53 |
|||
| Supports | First : | 9.64 | Second : | 8.06 |
| MAs | MA(5) : | 10.54 |
MA(20) : | 9.48 |
| MA(100) : | 9.36 |
MA(250) : | 8.51 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 83.8 |
D(3) : | 74.8 |
| RSI | RSI(14): 67.6 |
|||
| 52-week | High : | 12.34 | Low : | 3.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FDMT ] has closed It is unclear right now based on current values. 92.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.82 - 11.85 | 11.85 - 11.89 |
| Low: | 11.22 - 11.26 | 11.26 - 11.31 |
| Close: | 11.54 - 11.61 | 11.61 - 11.68 |
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Tue, 23 Jun 2026
4d molecular therapeutics CEO David Kirn sells $1.2m in stock By Investing.com - Investing.com South Africa
Tue, 23 Jun 2026
Insider Sell Alert: David Kirn Sells 114,746 Shares of 4D Molecu - GuruFocus
Tue, 23 Jun 2026
4d molecular therapeutics CEO David Kirn sells $1.2m in stock - Investing.com
Tue, 23 Jun 2026
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Tue, 23 Jun 2026
Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares - Stock Titan
Tue, 23 Jun 2026
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -69 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.228e+007 (%) |
| Held by Institutions | 3.883e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2853e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.57 |
| Profit Margin | -182.4 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 416.1 % |
| Return on Equity (ttm) | -21.5 % |
| Qtrly Rev. Growth | 8.824e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7143e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -4.53 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.219e+007 |
| Forward Dividend | 1.199e+007 |
| Dividend Yield | 104905000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|